Shaperon Inc. develops therapies based on GPCR19-inflammasome inhibitor platform and NanoMab antibody platform for immune diseases. It offers NuGel which blocks the root cause of atopic dermatitis that is in Phase 2 clinical trials; NuDifin that calms wound inflammation and accelerates the regeneration of tissue; NuRalin indicated for atopic dermatitis; NuAreatin for the treatment of alopecia areata. The company also provides NuCerin, a pill designed to reduce neuroinflammation; NuSepin, which alleviates excessive systemic inflammation; and NuPulin for the treatment of inflammation-driven pulmonary fibrosis. In addition, it offers Papiliximab, a NanoMab-based bispecific antibody that blocks PD-L1 and CD47 for leukemia treatment; Ovizumab, a tumor-specific immunotherapy; Regtizumab, an anti-tumor immunity; and Rbody, a NanoMabs’ small size which enables the creation of LNP-mRNA therapeutics. Further, the company provides RumiLua, a cosmeceutical ingredient to help prevent excessive skin responses while supporting the skin’s natural balance and overall condition. The company was founded in 2008 and is headquartered in Seoul, South Korea.
Metrics to compare | 378800 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship378800PeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.0x | −11.2x | −0.6x | |
PEG Ratio | −1.69 | −0.14 | 0.00 | |
Price/Book | 18.6x | 3.6x | 2.6x | |
Price / LTM Sales | 489.8x | 9.4x | 3.4x | |
Upside (Analyst Target) | - | 0.0% | 44.9% | |
Fair Value Upside | Unlock | 6.5% | 6.7% | Unlock |